Detalhe da pesquisa
1.
Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families.
Genet Med
; : 101171, 2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38828701
2.
Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases.
J Med Genet
; 60(4): 327-336, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36137616
3.
A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: application to BRCA1 and BRCA2.
Hum Mutat
; 20232023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38725546
4.
Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.
Breast Cancer Res
; 25(1): 53, 2023 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37161532
5.
Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2 breast cancer families.
J Med Genet
; 56(9): 581-589, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31186341
6.
Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.
Int J Cancer
; 143(4): 746-757, 2018 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29492969
7.
Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study.
Breast Cancer Res
; 19(1): 119, 2017 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29116004
8.
Genetic modifiers of CHEK2*1100delC-associated breast cancer risk.
Genet Med
; 19(5): 599-603, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27711073
9.
Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.
Breast Cancer Res
; 18(1): 104, 2016 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-27756439
10.
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Gynecol Oncol
; 141(2): 386-401, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-25940428
11.
Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis.
BMC Med
; 13: 156, 2015 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26137966
12.
A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.
BMC Cancer
; 15: 978, 2015 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-26674097
13.
Analysis of TP53 mutation status in human cancer cell lines: a reassessment.
Hum Mutat
; 35(6): 756-65, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24700732
14.
Growth and metastatic behavior of molecularly well-characterized human breast cancer cell lines in mice.
Breast Cancer Res Treat
; 148(1): 19-31, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25266129
15.
The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families.
Breast
; 73: 103611, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38039887
16.
Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.
Cancers (Basel)
; 16(4)2024 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38398132
17.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res
; 15(2): R33, 2013 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-23601657
18.
Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer.
Breast Cancer Res Treat
; 138(1): 47-57, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23338761
19.
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Nat Genet
; 31(1): 55-9, 2002 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-11967536
20.
Expression and Localization of Ferritin-Heavy Chain Predicts Recurrence for Breast Cancer Patients with a BRCA1/2 Mutation.
Cancers (Basel)
; 16(1)2023 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38201455